Target Name: CDCA2
NCBI ID: G157313
Other Name(s): FLJ25804 | Cell division cycle associated 2, transcript variant 1 | MGC129906 | recruits PP1 onto mitotic chromatin at anaphase protein | Cell division cycle-associated protein 2 | Repo-Man | CDCA2 variant 1 | Cell division cycle-associated protein 2 (isoform 1) | MGC129907 | Protein phosphatase 1 [gamma] (PPP1R3A) binding protein Repo-Man | PPP1R81 | Recruits PP1 onto mitotic chromatin at anaphase protein | cell division cycle associated 2 | protein phosphatase 1, regulatory subunit 81 | CDCA2_HUMAN

CDCA2 (FLJ25804) as a Drug Target and Biomarker: A Potential Target for Cancer Treatment

Abstract:
CDCA2 (FLJ25804) is a drug target and biomarker that has been identified for its potential role in cancer treatment. CDCA2 is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes, including cell division, apoptosis, and inflammation. Several studies have suggested that CDCA2 may be a potential drug target for cancer treatment, and research is ongoing to determine its efficacy and safety as a therapeutic approach.

Introduction:
Cancer is a leading cause of death worldwide, and its development and progression are a complex process that involves the interplay of multiple genetic and epigenetic factors. One of the key challenges in cancer treatment is the development of resistance to drugs, which can lead to a poor treatment outcome. The development of new drug targets and biomarkers can provide new approaches for cancer treatment and may help to improve the overall outcome for patients.

CDCA2 as a Drug Target:
CDCA2 has been identified as a potential drug target for cancer treatment due to its critical role in various cellular processes. CDCA2 is a non-coding RNA molecule that has been shown to play a critical role in cell division, apoptosis, and inflammation. Studies have shown that CDCA2 levels are regulated by various cellular factors, including the TGF-β pathway, which is a well-established mechanism for cancer development.

CDCA2 has been shown to be involved in the regulation of cell division, which is a critical process for cancer development. Several studies have shown that CDCA2 levels are regulated by the TGF-β pathway, which is a well-established mechanism for cancer development. This suggests that CDCA2 may be a potential drug target for cancer treatment.

CDCA2 has also been shown to play a critical role in apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body. Studies have shown that CDCA2 levels are regulated by various factors, including the production of pro-apoptotic transcription factors. This suggests that CDCA2 may be a potential drug target for cancer treatment.

CDCA2 has also been shown to play a critical role in inflammation, which is a complex process that involves the interplay of multiple genetic and epigenetic factors. Studies have shown that CDCA2 levels are regulated by various factors, including the production of pro-inflammatory cytokines. This suggests that CDCA2 may be a potential drug target for cancer treatment.

CDCA2 as a Biomarker:
CDCA2 has also been shown to be a potential biomarker for cancer treatment. Studies have shown that CDCA2 levels are regulated by various factors, including the production of cancer-associated biomarkers. This suggests that CDCA2 may be a potential biomarker for cancer diagnosis and treatment.

CDCA2 has been shown to be involved in the regulation of cell division, which is a critical process for cancer development. This suggests that CDCA2 may be a potential biomarker for cancer diagnosis and treatment.

CDCA2 has also been shown to play a critical role in apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body. This suggests that CDCA2 may be a potential biomarker for cancer diagnosis and treatment.

CDCA2 has also been shown to play a critical role in inflammation, which is a complex process that involves the interplay of multiple genetic and epigenetic factors. This suggests that CDCA2 may be a potential biomarker for cancer diagnosis and treatment.

Conclusion:
CDCA2 has been identified as a potential drug target and biomarker for cancer treatment. The regulation of

Protein Name: Cell Division Cycle Associated 2

Functions: Regulator of chromosome structure during mitosis required for condensin-depleted chromosomes to retain their compact architecture through anaphase. Acts by mediating the recruitment of phopsphatase PP1-gamma subunit (PPP1CC) to chromatin at anaphase and into the following interphase. At anaphase onset, its association with chromatin targets a pool of PPP1CC to dephosphorylate substrates

More Common Targets

CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L